Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal.

CONCLUSIONS: Among patients with advanced melanoma, significantly longer OS and PFS occurred with the combination of nivolumab plus ipilimumab or with nivolumab alone compared with ipilimumab alone. Furthermore, survival outcomes favoured the nivolumab-containing groups over the ipilimumab group in subgroup analyses. This article is protected by copyright. All rights reserved. PMID: 29766492 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29766492?dopt=Abstract

Source: The British Journal of Dermatology - May 15, 2018 Category: Dermatology Authors: Wan MT, Ming ME Tags: Br J Dermatol Source Type: research